• Mon, October 5, 2015
  • Wed, October 7, 2015
  • Fri, October 2, 2015
  • Tue, October 6, 2015

Matthew Harrison Upgraded (VRTX) to Buy and Increased Target to $148 on, Oct 2nd, 2015

Matthew Harrison of Morgan Stanley, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy and Increased Target from $118 to $148 on, Oct 2nd, 2015.

Matthew has made no other calls on VRTX in the last 4 months.



There are 4 other peers that have a rating on VRTX. Out of the 4 peers that are also analyzing VRTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Biren Amin of "Jefferies" Initiated at Hold and Held Target at $130 on, Wednesday, September 9th, 2015
  • Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $133 on, Monday, July 6th, 2015


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Jasper Hellweg of "Argus Research" Upgraded from Hold to Strong Buy on, Monday, September 28th, 2015
  • Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $148 on, Thursday, July 30th, 2015